These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 11503696

  • 1. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov 07; 65(216):66621-35. PubMed ID: 11503696
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Amendment to the current good manufacturing practice regulations for finished pharmaceuticals. Direct final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2007 Dec 04; 72(232):68064-70. PubMed ID: 18064770
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2011 Apr 13; 76(71):20513-8. PubMed ID: 21491807
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2004 Nov 24; 69(226):68611-88. PubMed ID: 15562555
    [Abstract] [Full Text] [Related]

  • 8. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule.
    Fed Regist; 1984 Aug 31; 49(171):34448-51. PubMed ID: 10299643
    [Abstract] [Full Text] [Related]

  • 9. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2007 Aug 24; 72(164):48765-801. PubMed ID: 17886394
    [Abstract] [Full Text] [Related]

  • 10. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug 03; 58(147):41348-54. PubMed ID: 10127711
    [Abstract] [Full Text] [Related]

  • 11. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 May 21; 64(98):27666-93. PubMed ID: 10558542
    [Abstract] [Full Text] [Related]

  • 12. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule.
    Fed Regist; 1999 Aug 19; 64(160):45366-74. PubMed ID: 10558597
    [Abstract] [Full Text] [Related]

  • 13. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2004 Apr 08; 69(68):18727-67. PubMed ID: 15072041
    [Abstract] [Full Text] [Related]

  • 14. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule.
    Fed Regist; 1999 May 14; 64(93):26282-7. PubMed ID: 10558530
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Status of certain additional over-the-counter drug category II and III active ingredients. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2002 May 09; 67(90):31123-5. PubMed ID: 12001971
    [Abstract] [Full Text] [Related]

  • 18. Blood and blood components; error and accident reports--Food and Drug Administration. Proposed rule.
    Fed Regist; 1980 Aug 08; 45(155):52821-4. PubMed ID: 10247831
    [Abstract] [Full Text] [Related]

  • 19. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
    Fed Regist; 1998 Dec 02; 63(231):66631-72. PubMed ID: 10338880
    [Abstract] [Full Text] [Related]

  • 20. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST, Pippins RR, Ngai JW.
    Food Drug Law J; 2009 Dec 02; 64(3):577-98. PubMed ID: 19999646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.